Mishima Gerhart
General Counsel bei PLIANT THERAPEUTICS, INC.
Profil
Mishima Gerhart is currently the Chief Regulatory Officer at Pliant Therapeutics, Inc. Prior to this, Mishima held positions as the Head-Regulatory Affairs at Genzyme Corp.
from 2014 to 2016, and as the Head-Global Regulatory Affairs at Sanofi from 2016 to 2020.
Mishima also served as the Chief Regulatory Officer & Head-Quality at Taysha Gene Therapies, Inc. Mishima's education includes an undergraduate degree from Kutztown University of Pennsylvania and a graduate degree from Temple University (Pennsylvania).
Aktive Positionen von Mishima Gerhart
| Unternehmen | Position | Beginn |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | General Counsel | 16.10.2023 |
Ehemalige bekannte Positionen von Mishima Gerhart
| Unternehmen | Position | Ende |
|---|---|---|
| SANOFI | General Counsel | 01.06.2020 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01.01.2016 |
| TAYSHA GENE THERAPIES, INC. | General Counsel | - |
Ausbildung von Mishima Gerhart
| Kutztown University of Pennsylvania | Undergraduate Degree |
| Temple University (Pennsylvania) | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| SANOFI | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
